Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck Outlines Plans For 2009 NDA Filings; Migraine Drug Is Best Bet

Executive Summary

Merck's fledgling bioventures business may have dominated headlines following the company's recent analyst day, but the firm's other initiatives are likely to contribute more to near-term growth as Merck tries to address the revenue gap that will be left by key patent expirations in the next few years

You may also be interested in...



Merck U.S. Restructuring Not To Blame For Q1 Sales Drop, Execs Say

Merck is assuring analysts that its massive commercial restructuring continues to benefit, not stifle, product growth, as company executives reported lower-than-expected sales and earnings April 21

Merck U.S. Restructuring Not To Blame For Q1 Sales Drop, Execs Say

Merck is assuring analysts that its massive commercial restructuring continues to benefit, not stifle, product growth, as company executives reported lower-than-expected sales and earnings April 21

Merck’s Ambitious Plans For Follow-On Biologics

Merck outlined ambitious plans for launching and growing a follow-on biologics business during its annual business briefing Dec. 9

Related Content

UsernamePublicRestriction

Register

PS050476

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel